VERV Verve Therapeutics
- 6.260
- +0.100+1.62%
- 6.420
- +0.160+2.56%
Verve Therapeutics News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Verve Therapeutics, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating c
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
Top 10 Worst Performing Cathie Wood ARKK Holdings of 2024
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite the stock's positive market performance on the same day.The COIN TradeAr
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
On Wednesday, Cathie Wood's Ark Invest made a significant move by purchasing additional shares of Pinterest Inc (NYSE:PINS).The PINS TradeArk Invest's Fintech Innovation ETF (NYSE:ARKF) acquired 26,92
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
Verve Therapeutics Is Maintained at Buy by Stifel
Verve Therapeutics Is Maintained at Buy by Stifel
Express News | Stifel Maintains Buy on Verve Therapeutics, Lowers Price Target to $40
Verve Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/03/2024 376.19% Stifel $56 → $40 Maintains Buy 02/28/2024 316.67% RBC Capital → $35 Reiterates Outperfo
Buy Rating Affirmed for Verve Therapeutics With Strategic Focus on Promising VERVE-102 Program
Sector Update: Health Care Stocks Slide Late Afternoon
Health care stocks fell late Tuesday afternoon with the NYSE Health Care Index down 1.5% and the Health Care Select Sector SPDR Fund (XLV) dropping 1.6%. The iShares Biotechnology ETF (IBB) fell 2.2%.
Express News | Beam Therapeutics Shares Are Trading Lower After Verve Therapeutics Paused Enrollment in Its Heart-1 Clinical Trial. Verve and Beam Previously Entered a License Agreement for Access to Beam's Base Editing, Gene Editing, and Delivery Technologies
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics Inc (NASDAQ:VERV) announced an update from the Heart-1 Phase 1b trial of VERVE-101.
Verve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock Falls
Canopy Growth, Exact Sciences, Stereotaxis Among Healthcare Movers
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday
Health care stocks were leaning lower premarket Tuesday, with the Health Care Select Sector SPDR Fund (XLV) retreated 1%, while the iShares Biotechnology ETF (IBB) was flat. Verve Therapeutics (VERV)
Analysis
Price Target
No Data
